Vivus (VVUS +0.2%) shares reverse course after suffering heavy losses earlier and hover around...
Vivus (VVUS +0.2%) shares reverse course after suffering heavy losses earlier and hover around zero after USA Today reports that the FDA has approved its Qnexa/Qysemia diet drug. However, no other news organizations appear to have reported the story, and it's not on the FDA website. Update: the linked-story in this MC seems to have been taken down. Vivus shares -0.6%.
From other sites
at CNBC.com (Dec 2, 2014)
at CNBC.com (Dec 1, 2014)
at CNBC.com (Oct 27, 2014)
at CNBC.com (Sep 18, 2014)
at CNBC.com (Sep 11, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs